Legal Developments Affecting the Life Sciences Industry Conference

Legal Developments Affecting the Life Sciences Industry Conference

Speaking Engagement

WilmerHale will host its inaugural Legal Developments Affecting the Life Sciences Industry Conference on Tuesday, October 6. The program will run from 12–4 p.m. and feature firm partners as well as speakers from leading pharmaceutical companies on the following panels:

Trends in Post-Grant Proceedings (optional working lunch)

  • Impact of Amgen v. Sandoz on biosimilar IPRs
  • Empirical evidence on IPRs against Orange Book listed patents
  • Strategies for success in defending IPRs for life sciences companies

Developments in the FTC's Enforcement and Private Antitrust Litigation

  • How have courts applied the “rule of reason” standard announced in Actavis?
  • What are the emerging antitrust standards governing launch or promotion of "next generation" products, and withdrawal of legacy products?
  • REMS: Are innovator drug companies obligated under the antitrust law to provide samples to generics conducting bioequivalence testing for future ANDAs?

Recent Happenings at the Supreme Court and Federal Circuit and What to Look for in the Future

  • Discussion and analysis of recent case law from the Supreme Court and Federal Circuit of particular import for the life sciences

Rules and Guidelines for the Filing and Defense of Hatch-Waxman (ANDA) and Other Life Sciences Litigation

  • Applicable procedural and ethical rules
  • Requirements at various litigation stages, particularly in light of the impending amendments to the Federal Rules of Civil Procedure
  • Consequences for the unwary litigant, including potential sanctions, "negative inference" presumptions, rejection of expert testimony or outright dismissal

This educational event will conclude with a networking cocktail reception. CLE credit will be offered, including ethics credit.

Read More About the Event



Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.